The content on this site is intended for healthcare professionals only
Dr Hans-Christian Kolberg speaks to ecancer about the rationale for routine use of intraoperative radiotherapy (IORT) for early breast cancer and data for specific indications.
He outlines the use of IORT in clinical routine examining the background and results of a variety of clinical trials such as the TARGIT-A trial.
Dr Kolberg also presents the use of IORT in specific indications using his own data and experiences after over 1000 cases.
He concludes that in selected patients IORT can today be offered as the only radiation which does not compromise the oncological outcomes. However, the possible beneficial effect of IORT on non-breast cancer mortality requires further investigation.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
Neo-adjuvant therapy for different cancers in the Philippines
The pros and cons of breast IORT and ultra hypofractionation (FR)
Global adoption of single-shot targeted IORT for breast cancer
IORT at the Asian Hospital and Medical Center
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
